SCHEDULE 13D/A: Key Investors Increase Stake in GeneDx Holdings Corp., Boosting Beneficial Ownership

A group of significant investors, including Eli Casdin and Keith Meister, have increased their beneficial ownership in GeneDx Holdings Corp., with their collective stake now reaching up to 14.2% of Class A common stock.

Summary

• This is Amendment No. 8 to the Schedule 13D filing for GeneDx Holdings Corp. (formerly Sema4 Holdings Corp.), updating beneficial ownership information.
• Eli Casdin and entities he controls (Casdin Capital, LLC, Casdin Partners Master Fund, L.P., Casdin Partners GP, LLC) collectively beneficially own 4,096,095 shares, representing 14.2% of the Class A common stock.
• Keith A. Meister and entities he controls (Corvex Management LP) collectively beneficially own 3,477,250 shares, representing 12.1% of the Class A common stock.
• CMLS Holdings LLC, C-LSH LLC, and M-LSH LLC, jointly controlled by Mr. Casdin and Mr. Meister, beneficially own 537,285 shares, representing 1.9% of the Class A common stock.
• The percentages are based on 28,533,204 Class A common shares outstanding as of April 23, 2025, as reported in the Issuer's Form 10-Q filed on April 30, 2025.
• Recent acquisitions by Casdin Partners Master Fund, LP include 100,000 shares on June 3, 2024, for $2,081,640, and 30,000 shares on June 4, 2024, for $675,477.
• A cross-trade occurred on August 1, 2024, where Casdin Partners FO1-MSV, LP transferred 413,655 shares to Casdin Partners Master Fund, L.P. for $13,340,373.75.
• Corvex Management LP acquired additional shares in open market transactions: 158,347 shares on May 2, 2025, at a weighted average price of $63.76 per share; 152,533 shares on May 5, 2025, at $65.37 per share; and 123,968 shares on May 6, 2025, at $62.45 per share.
• Eli Casdin's beneficial ownership includes shares issuable from private placement warrants (204,141 shares exercisable at $379.50 per share), vested options (11,882 shares), and restricted stock units (7,593 vested, 12,924 vesting within 60 days).
• Keith Meister's beneficial ownership also includes shares issuable from private placement warrants (204,141 shares exercisable at $379.50 per share), vested options (11,207 shares), and restricted stock units (7,205 vested, 12,924 vesting within 60 days).

Sentiment

Score: 7

Explanation: The increased beneficial ownership by prominent investors suggests a positive outlook and confidence in the company, which is generally a favorable signal for the market.

Positives

• Increased beneficial ownership by prominent investors Eli Casdin and Keith Meister signals strong confidence in GeneDx Holdings Corp.'s future prospects.
• The continued accumulation of shares by these key investors, including recent open market purchases by Corvex Management LP, suggests a positive long-term outlook from sophisticated market participants.

Risks

• A significant portion of the beneficial ownership for Eli Casdin and Keith Meister includes shares issuable from private placement warrants with a high exercise price of $379.50 per share, which is substantially above recent market acquisition prices, potentially indicating a long path to profitability for these specific holdings or a risk of non-exercise if the stock price does not reach this level.
• The filing of a Schedule 13D, particularly by investors with a history of activism, could imply potential for future strategic demands or changes, which while not explicitly stated as a risk, is an inherent characteristic of such filings.

Future Outlook

The document primarily details changes in beneficial ownership and does not provide explicit forward-looking statements or guidance from GeneDx Holdings Corp. itself. However, the increased stake by significant investors like Eli Casdin and Keith Meister, who are also board members, could be interpreted as a positive signal regarding their confidence in the company's future trajectory.

Industry Context

This filing reflects a significant increase in ownership by key institutional investors in GeneDx Holdings Corp., a company in the genomics and diagnostic testing sector. Such increased stakes by prominent investors often signal a belief in the company's long-term value proposition or potential for strategic changes, which can influence broader market perception within the industry.

Related Party Transactions

• On August 1, 2024, Casdin Partners FO1-MSV, LP transferred 413,655 shares in a cross-trade to Casdin Partners Master Fund, L.P. for an aggregate purchase price of $13,340,373.75. Both entities are managed by Casdin Capital, LLC, and Eli Casdin.

Stakeholder Impact

• Shareholders may view the increased stake by prominent investors as a positive indicator of future value, potentially boosting investor confidence and share price.
• The presence of significant activist investors on the board (Eli Casdin and Keith Meister) could lead to strategic initiatives that may impact employees, customers, and suppliers, though no specific plans are detailed in this filing.

Key Dates

Recommendation

Keywords

GeneDx Holdings Corp, GDHC, SEC filing, Schedule 13D, beneficial ownership, institutional investment, Casdin Capital, Corvex Management, Eli Casdin, Keith Meister, Class A common stock, investor stake, equity acquisition